Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product

Abstract Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin thera...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stuart D. Dowall, Frédéric Jacquot, John Landon, Emma Rayner, Graham Hall, Caroline Carbonnelle, Hervé Raoul, Delphine Pannetier, Ian Cameron, Ruth Coxon, Ibrahim Al Abdulla, Roger Hewson, Miles W. Carroll
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7b63ac3978a941a387227fe5cf54b86d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b63ac3978a941a387227fe5cf54b86d
record_format	dspace
spelling	oai:doaj.org-article:7b63ac3978a941a387227fe5cf54b86d2021-12-02T12:32:19ZPost-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product10.1038/s41598-017-03910-72045-2322https://doaj.org/article/7b63ac3978a941a387227fe5cf54b86d2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03910-7https://doaj.org/toc/2045-2322Abstract Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBOV infection. To ensure stringent therapeutic testing conditions to replicate likely clinical usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV. Results showed a protective effect of EBOTAb given post-exposurally, with survival rates decreasing with increasing time after challenge. Viremia results demonstrated that EBOTAb resulted in a decreased circulation of EBOV in the bloodstream. Additionally, assay of liver enzymes and histology analysis of local tissues identified differences between EBOTAb-treated and untreated groups. The results presented demonstrate that EBOTAb conferred protection against EBOV when given post-exposure and should be explored and developed further as a potential intervention strategy for future outbreaks, which are likely to occur.Stuart D. DowallFrédéric JacquotJohn LandonEmma RaynerGraham HallCaroline CarbonnelleHervé RaoulDelphine PannetierIan CameronRuth CoxonIbrahim Al AbdullaRoger HewsonMiles W. CarrollNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-15 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Stuart D. Dowall Frédéric Jacquot John Landon Emma Rayner Graham Hall Caroline Carbonnelle Hervé Raoul Delphine Pannetier Ian Cameron Ruth Coxon Ibrahim Al Abdulla Roger Hewson Miles W. Carroll Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
description	Abstract Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBOV infection. To ensure stringent therapeutic testing conditions to replicate likely clinical usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV. Results showed a protective effect of EBOTAb given post-exposurally, with survival rates decreasing with increasing time after challenge. Viremia results demonstrated that EBOTAb resulted in a decreased circulation of EBOV in the bloodstream. Additionally, assay of liver enzymes and histology analysis of local tissues identified differences between EBOTAb-treated and untreated groups. The results presented demonstrate that EBOTAb conferred protection against EBOV when given post-exposure and should be explored and developed further as a potential intervention strategy for future outbreaks, which are likely to occur.
format	article
author	Stuart D. Dowall Frédéric Jacquot John Landon Emma Rayner Graham Hall Caroline Carbonnelle Hervé Raoul Delphine Pannetier Ian Cameron Ruth Coxon Ibrahim Al Abdulla Roger Hewson Miles W. Carroll
author_facet	Stuart D. Dowall Frédéric Jacquot John Landon Emma Rayner Graham Hall Caroline Carbonnelle Hervé Raoul Delphine Pannetier Ian Cameron Ruth Coxon Ibrahim Al Abdulla Roger Hewson Miles W. Carroll
author_sort	Stuart D. Dowall
title	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
title_short	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
title_full	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
title_fullStr	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
title_full_unstemmed	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product
title_sort	post-exposure treatment of non-human primates lethally infected with ebola virus with ebotab, a purified ovine igg product
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/7b63ac3978a941a387227fe5cf54b86d
work_keys_str_mv	AT stuartddowall postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT fredericjacquot postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT johnlandon postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT emmarayner postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT grahamhall postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT carolinecarbonnelle postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT herveraoul postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT delphinepannetier postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT iancameron postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT ruthcoxon postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT ibrahimalabdulla postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT rogerhewson postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct AT mileswcarroll postexposuretreatmentofnonhumanprimateslethallyinfectedwithebolaviruswithebotabapurifiedovineiggproduct
_version_	1718394103068098560

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product

Ejemplares similares